• Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8
• The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options
• CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). In the recent Emerging Growth Conference 73 on July 17-18, 2024, CEO Rob Etherington and CFO Morgan Brown presented new findings and information about the company and its lead drug candidate, pertinent to current and potential investors.

In the opening of the presentation, Etherington explained that mitochondria play a vital role in cellular metabolism and energy production, and that impaired mitochondrial function is a significant issue in neurodegenerative diseases. Clene’s lead agent, CNM-Au8(R), works by improving cellular energy…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN